Results 21 to 30 of about 4,303 (127)

Long-term anti-PF4 persistence in autoimmune heparin-induced thrombocytopenia: A glimpse into the natural history of vaccine-induced immune thrombotic thrombocytopenia

Thrombosis Update, 2021
Vaccine-induced immune thrombotic thrombocytopenia has been described after adenoviral-based vaccine administration for COVID-19. Similar to autoimmune heparin-induced thrombocytopenia (aHIT), there exists a potential for long-term persistence of anti ...
Guillaume Roberge, Dimitrios Scarvelis
doaj   +1 more source

VITT with inactivated SARS-CoV-2 vaccine – index case

Human Vaccines & Immunotherapeutics, 2022
We report a case of vaccine-induced immune thrombotic thrombocytopenia (VITT) in a 73-year-old gentleman who presented with pulmonary embolism and thrombocytopenia, two weeks after receiving inactivated COVID-19 vaccine.
Kanta Devi, Natasha Ali, Nosheen Nasir, Syed Faisal Mahmood   +3 more
doaj   +1 more source

Thrombotic thrombocytopenic purpura following ChAdOx1 nCov-19 vaccination: A case report

IDCases, 2023
Vaccine-associated thrombotic thrombocytopenic purpura (TTP) is a rare type of acquired TTP recently reported after COVID-19 vaccination. Merely four cases are ascribed to the ChAdOx1 nCoV-19 vaccine in the medical literature till the preparation of this
Bahareh Shateri Amiri, Hanieh Radkhah, Reza Taslimi, Zahra Shahbazi Dastjerdi, Mohamad Mehdi Khadembashiri, Milad Gholizadeh Mesgarha, Shiva Rahimipour Anaraki   +6 more
doaj   +1 more source

Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature

Journal of Medical Case Reports, 2023
Background Immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura are both causes of thrombocytopenia. Recognizing thrombotic thrombocytopenic purpura is crucial for subsequent treatment and prognosis.
Hung-Chen Lin, Jinxiang Huang, Jing Huang, Li-Jun Zhang, Xiao-Wu Yin, Jian-Cheng Yang, Xiao-Yan Huang   +6 more
doaj   +1 more source

Treatment of drug-induced immune thrombocytopenias

Haematologica, 2022
Several therapeutic agents can cause thrombocytopenia by either immune-mediated or non-immune-mediated mechanisms. Non-immune-mediated thrombocytopenia is due to direct toxicity of drug molecules to platelets or megakaryocytes.
Irene Marini, Gunalp Uzun, Kinan Jamal, Tamam Bakchoul   +3 more
doaj   +1 more source

Case Report of Cerebral Sinus Thrombosis Related to Immune Thrombotic Thrombocytopenia Following Administration of ChAdOx1 nCoV-19 for Vaccination against COVID-19

Life, 2022
Vaccine-induced immune thrombotic thrombocytopenia (VITT) with cerebral venous sinus thrombosis (CVST) has been recently reported after vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Wojciech Szypowski, Aleksander Dębiec, Jarosław Świstak, Maciej Nowocień, Piotr Rzepecki, Marcin Możański, Jacek Staszewski, Adam Stępień   +7 more
doaj   +1 more source

Platelet Activation Mechanisms and Consequences of Immune Thrombocytopenia

Cells, 2021
Autoimmune disorders are often associated with low platelet count or thrombocytopenia. In immune-induced thrombocytopenia (IIT), a common mechanism is increased platelet activity, which can have an increased risk of thrombosis.
Siyu Sun, Rolf T. Urbanus, Hugo ten Cate, Philip G. de Groot, Bas de Laat, Johan W. M. Heemskerk, Mark Roest   +6 more
doaj   +1 more source

COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A review

Annals of Thoracic Medicine, 2022
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19).
Malay Sarkar, Irappa V Madabhavi, Pham Nguyen Quy, Manjunath B Govindagoudar   +3 more
doaj   +1 more source

COVID-19 Adenoviral Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT), COVID-19-Related Thrombosis, and the Thrombotic Thrombocytopenic Syndromes

Hematology Reports, 2022
Adenoviral-based vaccines such as ChadoX1 CoV-19 (AstraZeneca) and Ad26.COV2.S (J&J) were developed to prevent infection and reduce hospitalization or death in Coronavirus Disease 2019 (COVID-19) patients.
Gewil Daniella Olipas Allas, Joekeem Del Rosario Arizala, Rafael Vincent Mercado Manalo   +2 more
doaj   +1 more source

Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand

Thrombosis Journal, 2021
Background Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but fatal complication of the Coronavirus Disease 2019 vaccine. The many reports of VITT have mostly been in the Caucasian population. Here, we present the first reported case
Archrob Khuhapinant, Tarinee Rungjirajittranon, Bundarika Suwanawiboon, Yingyong Chinthammitr, Theera Ruchutrakool   +4 more
doaj   +1 more source